GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aerocrine AB (LTS:0O35) » Definitions » Net Current Asset Value

Aerocrine AB (LTS:0O35) Net Current Asset Value : kr0.31 (As of Mar. 2015)


View and export this data going back to . Start your Free Trial

What is Aerocrine AB Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Aerocrine AB's net current asset value per share for the quarter that ended in Mar. 2015 was kr0.31.

The historical rank and industry rank for Aerocrine AB's Net Current Asset Value or its related term are showing as below:

LTS:0O35's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.92
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Aerocrine AB Net Current Asset Value Historical Data

The historical data trend for Aerocrine AB's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerocrine AB Net Current Asset Value Chart

Aerocrine AB Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.06 0.58 0.20 -0.43

Aerocrine AB Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.10 -0.26 -0.43 0.31

Competitive Comparison of Aerocrine AB's Net Current Asset Value

For the Medical Devices subindustry, Aerocrine AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerocrine AB's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aerocrine AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Aerocrine AB's Price-to-Net-Current-Asset-Value falls into.



Aerocrine AB Net Current Asset Value Calculation

Aerocrine AB's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2014 is calculated as

Net Current Asset Value Per Share(A: Dec. 2014 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(201.286-345.697-0-0)/339.53
=-0.43

Aerocrine AB's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2015 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2015 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(561.134-343.754-0-0)/698.766
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerocrine AB  (LTS:0O35) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Aerocrine AB Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Aerocrine AB's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerocrine AB (LTS:0O35) Business Description

Traded in Other Exchanges
N/A
Address
Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. The company offers exhaled nitric oxide (NO) monitoring devices for research and clinical applications. Aerocrine's devices utilize methods for measuring minute concentrations of NO, and incorporate NO scrubbers to eliminate atmospheric NO from the patient's breath. Measuring NO values helps doctors differentiate asthma from similar conditions, and differentiate various forms of asthma from other airway diseases. The company markets two products globally namely NIOX Flex and NIOX MINO. These products are widely used by primary care asthma specialists in Europe, and have recently gained US regulatory approval. Distribution agreements have also been signed in Japan, and regulatory approval has been secured in China. The company has offices and subsidiaries in Sweden, Germany, the United States, and the United Kingdom. The parent company is located in Solna, Sweden, and has sales enterprises in Sweden, Germany, the United States, and the United Kingdom. NIOX was replaced by its successor, NIOX FLEX in 2007. NIOX FLEX was the first tailor-made device for measuring exhaled nitric oxide (NO). NIOX FLEX includes enhanced data handling facilities, add-on research kits, and USB ports for communication. Moreover, a new application, NIOX Flex Flow, can determine whether lung inflammation is located centrally or more peripherally, which can be highly significant to therapy choices. The Nasal Research Kit allows measurement of nasal NO, while the FlexFlo Research Kit enables measurement of exhaled NO at variable flow rates, to help identify the location of inflammation. NIOX MINO is a compact hand-held device, marketed for smaller clinics, healthcare centers, and hospitals. NIOX MINO is intended for routine measurements of NO. Patients hold the NIOX MINO and breathe into the mouthpiece. An audible tone helps patient maintain the right flow during exhalation, whereupon results are displayed on the front of the device.

Aerocrine AB (LTS:0O35) Headlines

No Headlines